Is
a mind lift ethical? Researchers debate the dilemma of boosting
brainpower
By AMY ADAMS
For decades people have nipped a wrinkle here, reduced a nose
size there or paid for help boosting test scores. With this history
of paying to improve our bodies and minds, why not extend that
liberty to memory-improving drugs or brain-enhancing implants?
These and other questions being raised by modern neuroscience were
the topic of a meeting of neuroscientists, ethicists and
psychologists funded by the National Science Foundation and the New
York Academy of Sciences. The group, led by Judy Illes, senior
research scholar in biomedical ethics and in radiology at the
School of Medicine, published their thoughts in a recent online
issue of Nature Reviews Neuroscience. The article will
also appear in the May print issue of the journal. The group's
goals were to outline both the ethical issues raised by modern
neuroscience and the steps scientists should take, if any.
Plastic surgery and neural enhancement both raise safety issues,
Illes said. However, she and co-chair Martha Farah, PhD, professor
of psychology at the University of Pennsylvania, feel the risks are
more acceptable when treating an illness rather than taking normal,
healthy people and trying to make them better.
Illes said the key difference between physical enhancements such as
plastic surgery and neural enhancement through drugs or brain
implants comes down to personhood. A nose job doesn't change who
you are. Drugs might, she said. "Am I the same person on Ritalin as
off?" Farah asked.
Farah said there have been no studies that establish the long-term
effects of brain function in children who take Ritalin to control
hyperactivity or in people who take medication for depression. It
could be that drugs alter the way the brain works, fundamentally
changing personality. The drugs may even have unanticipated
consequences such as speeding the brain's decline with old age.
The question becomes more complicated for drugs such as modafinil,
which can improve memory or the ability to concentrate. These have
obvious appeal for professionals wanting an edge, but at what cost?
"I think it is important for science to move forward," Illes said.
"I worry about how the science will be conveyed to the public. Will
it play on fears of not having a competitive edge?"
If the answer is yes, Illes brings up a few hypothetical
situations. What if some people in a given field take a drug to
make themselves doubly productive? Will their productivity put
pressure on colleagues to use the drugs, much like some
professional athletes feel competitive pressure to take steroids?
Would differences in productivity cause conflicts between
colleagues or inequalities in pay?
These scenarios raise issues about what scientists should do to
prevent the abuse of brain enhancement research. In their review,
Illes and her colleagues quote Francis Fukuyama, the Omer L. and
Nancy Hirst Professor of Public Policy at the Institute of Public
Policy at George Mason University, who has called for legislation
to control the use of drugs or devices that alter the way the brain
functions.
Legislation isn't necessary, according to the group, but caution
is. Illes and Farah argue that by being proactive in thinking about
ethical issues, ethicists, neurologists and physicians can develop
guidelines to aid decisions about how research findings are used
and communicated to the public.
Robert Cook-Deegan, MD, director of Duke Institute for Genome
Sciences and Policy's Center for Genome Ethics, Law and Policy,
hopes that such guidelines will distinguish between potentially
harmful brain alterations and the type of brain-altering activities
that have taken place since the dawn of civilization. Every time a
person smokes a cigarette, drinks a glass of wine or wakes up with
a cup of coffee, the workings of that person's brain are being
changed, he said, so how is taking a drug any different?
"Caffeine then modafinil; what is next?" said Cook-Deegan, a
co-author of the paper.
Cook-Deegan said drug treatments follow a well-trammeled path from
development for treating a disease, such as depression, Alzheimer's
or narcolepsy, to use for less established medical conditions. The
drug Ritalin, used to treat children with attention deficit
hyperactivity disorder, is a classic example. Where it was once a
welcome relief to those rare parents with hard-to-manage kids, the
drug is now widely prescribed and is even taken by college students
needing help focusing before exams.
In addition to drugs, Illes said that modern brain imaging
techniques may reveal aspects of personality such as a tendency to
lie or be aggressive. As the technology improves doctors must
decide who should have access to this information and whether they
should treat a neural tendency rather than an actual behavior.
![](../../gifs/srdot.gif)
|
![](gifs/illes.jpg)
Judy Illes
Risks
vs. benefits of self-referred CT scanning weighed (8/6/03)
Researcher's
letter raises ethics issue (3/5/03)
|